Cardiovascular Risk Factors in Transgender People after Gender-Affirming Hormone Therapy

Author:

Sánchez-Toscano Esteban12ORCID,Domínguez-Riscart Jesús23ORCID,Larrán-Escandón Laura1,Mateo-Gavira Isabel12,Aguilar-Diosdado Manuel124ORCID

Affiliation:

1. Endocrinology and Nutrition Department, Puerta del Mar University Hospital, 11009 Cádiz, Spain

2. Biomedical Research and Innovation Institute of Cádiz (INiBICA), 11009 Cádiz, Spain

3. Pediatrics and Specific Areas Department, Puerta del Mar University Hospital, 11009 Cádiz, Spain

4. School of Medicine, Cadiz University (UCA), 11003 Cádiz, Spain

Abstract

Introduction: In the last decade, healthcare for the transgender population has increased considerably in many countries thanks to depathologization movements and the easier accessibility of medical assistance. The age at which they request to start gender-affirming hormones (GAHs) is increasingly younger. The cardiovascular risk associated with hormonal treatment is a novel research field, and the published studies are heterogeneous and inconclusive. Our objective is to determine the metabolic impact of GAHs in the transgender people treated in our Gender Identity Treatment Unit. Methods: We designed a pre–post study to analyze changes in anthropometric parameters (weight and body mass index), analytical determinations (fasting blood glucose, glycated hemoglobin, and lipoproteins), and blood pressure control in the transgender population treated with GAHs in Puerta del Mar University Hospital. These variables were collected before and one year after hormonal therapy. Results: A total of 227 transgender people were recruited between 2017 and 2020, 97 (40.09%) transwomen and 136 (59.91%) transmen. The average age at which GAHs began was 18 years. Weight, body mass index, and blood pressure increased significantly in both genders. Transmen showed a more atherogenic lipid profile, with a decrease in cholesterol LDL (p < 0.001) and an increase in triglycerides (p < 0.001). The risk of developing prediabetes or diabetes did not increase one year after treatment, although non-specific alterations in carbohydrate metabolism were detected, such as an increase in glycated hemoglobin in transmen (p = 0.040) and fasting blood glucose in transwomen (p = 0.008). No thromboembolic processes or cardiovascular events were reported during the first year of treatment. Conclusion: In our setting, transgender people developed changes in their metabolic profiles in the first year after hormonal treatment. Both transmen and transwomen showed early alterations in lipid and carbohydrate metabolism, slight elevations in blood pressure, and a tendency to gain weight. This makes lifestyle interventions necessary from the beginning of GAHs.

Funder

Andalusian Endocrinology and Nutrition Society

Publisher

MDPI AG

Subject

General Medicine

Reference41 articles.

1. Acute Clinical Care for Transgender Patients: A Review;Rosendale;JAMA Intern. Med.,2018

2. Gender Affirming Medical Care of Transgender Youth;Sequeira;Curr. Probl. Pediatr. Adolesc. Health Care,2019

3. Andalusian Ministry of Health (2016). Integrated Healthcare Assistance Process for Adult Transgender Individuals, Regional Government of Andalusia.

4. New care models for transgender people in the Spanish Health System: Demands, controversies and reflections;Rev. Esp. Salud Publica,2020

5. Review: Puberty Blockers for Transgender and Gender Diverse Youth-A Critical Review of the Literature;Rew;Child. Adolesc. Ment. Health,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3